18
Aug
Nestlé is seeking to turn the rapid growth of GLP-1 weight-loss drugs into a business opportunity by developing nutrition products tailored to users of medicines such as Ozempic and Wegovy. The company is using artificial intelligence and nutritional science to study clinical research, identify nutrient combinations and develop products aimed at addressing challenges associated with rapid weight loss, including muscle loss, dehydration and reduced nutritional intake. Nestlé has already introduced products such as Boost Advanced Nutrition Shake in the US, containing 35 grams of protein, while a higher-protein version of Milo has been launched in Asia and Australia. Its Vital…
